Methylation of NRIP3 Is a Synthetic Lethal Marker for Combined PI3K and ATR/ATM Inhibitors in Colorectal Cancer
Open Access
- 18 January 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (3) , e00682
Abstract
INTRODUCTION: The aim of this study was to investigate the epigenetic regulation and underlying mechanism of NRIP3 in colorectal cancer (CRC). METHODS: Eight cell lines (SW480, SW620, DKO, LOVO, HT29, HCT116, DLD1, and RKO), 187 resected margin samples from colorectal cancer tissue, 146 cases with colorectal adenomatous polyps, and 308 colorectal cancer samples were used. Methylation-specific PCR, Western blotting, RNA interference assay, and a xenograft mouse model were used. RESULTS: NRIP3 exhibited methylation in 2.7% (5/187) of resected margin samples from colorectal cancer tissue, 32.2% (47/146) of colorectal adenomatous polyps, and 50.6% (156/308) of CRC samples, and the expression of NRIP3 was regulated by promoter region methylation. The methylation of NRIP3 was found to be significantly associated with late onset (at age 50 years or older), poor tumor differentiation, lymph node metastasis, and poor 5-year overall survival in CRC (all P < 0.05). In addition, NRIP3 methylation was an independent poor prognostic marker (P < 0.05). NRIP3 inhibited cell proliferation, colony formation, invasion, and migration, while induced G1/S arrest. NRIP3 suppressed CRC growth by inhibiting PI3K-AKT signaling both in vitro and in vivo. Methylation of NRIP3 sensitized CRC cells to combined PI3K and ATR/ATM inhibitors. DISCUSSION: NRIP3 was frequently methylated in both colorectal adenomatous polyps and CRC. The methylation of NRIP3 may potentially serve as an early detection, late-onset, and poor prognostic marker in CRC. NRIP3 is a potential tumor suppressor. NRIP3 methylation is a potential synthetic lethal marker for combined PI3K and ATR/ATM inhibitors.Keywords
Funding Information
- National Key Research and Development Program of China (2018YFA0208902)
- National Key Research and Development Program of China (2020YFC2002705)
- National Natural Science Foundation of China (82272632)
- National Natural Science Foundation of China (81672138)
- National Natural Science Foundation of China (U1604281)
- Beijing Science Foundation of China (7171008)
- Youth Innovation Science Foundation of Chinese PLA general hospital (22QNCZ027)
This publication has 43 references indexed in Scilit:
- Akt: A Double-Edged Sword in Cell Proliferation and Genome StabilityJournal of Oncology, 2012
- Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling PathwayPLOS ONE, 2010
- Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2Journal of Cell Biology, 2010
- The Transcriptional Coregulator RIP140 Represses E2F1 Activity and Discriminates Breast Cancer SubtypesClinical Cancer Research, 2010
- AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51Cancer Research, 2008
- Promoter methylation ofHIN-1in the progression to esophageal squamous cancerEpigenetics, 2008
- Nuclear Receptor Structure: Implications for FunctionAnnual Review of Physiology, 2007
- Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the EsophagusClinical Cancer Research, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Characterization of Four Autonomous Repression Domains in the Corepressor Receptor Interacting Protein 140Journal of Biological Chemistry, 2004